Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris

NCT04661709 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 502

Last updated 2021-01-25

No results posted yet for this study

Summary

This is a double-blind, randomized placebo-controlled trial which aims to evaluate the efficacy and safety of Wen Xin granule in patients with unstable angina pectoris.

Conditions

Interventions

DRUG

Wen Xin granule

one dose daily, two times per day.

DRUG

Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet

one tablet daily. (for patients who can't use aspirin)

DRUG

Atorvastatin Calcium

20 mg tablet, one tablet each night.

DRUG

Isosorbide Mononitrate Tab 20 MG

one tablet, twice daily.

DRUG

Metoprolol Tartrate Tab 25 MG

12.5 mg or 25 mg, two times daily.

DRUG

Aspirin Enteric-coated Tablets

100mg tablet, one tablet daily.

DRUG

WXG placebo

one dose daily, two times per day.

DRUG

Trimetazidine Dihydrochloride Tablets

20 mg tablet, one tablet three times daily.

DRUG

glyceryl trinitrate

be taken when angina pectoris attacks.

Sponsors & Collaborators

  • Special Project of National Traditional Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine

    collaborator UNKNOWN
  • National Natural Science Foundation of China

    collaborator OTHER_GOV
  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Jun Li, M.D. · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2023-03-01
Completion
2023-06-01

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04661709 on ClinicalTrials.gov